A new study, published in The Journal of Clinical Investigation, examined whether tissue-resident memory CD8+ T cells (TRM) in the brain can prevent the development of brain tumors and whether these protective immune cells can be generated through vaccination. Because brain tumors often resist conventional immunotherapies due to the unique immune environment of the central nervous system, researchers hypothesized that establishing tumor-specific TRM in healthy brain tissue before cancer develops could provide long-lasting protection against intracranial malignancy.

Using mouse models, investigators generated tumor-specific brain TRM through peripheral immunization approaches, including dendritic cell/Listeria-based vaccination and a clinically relevant mRNA-lipid nanoparticle (mRNA-LNP) vaccine platform. Mice were then challenged with intracranial melanoma or glioblastoma tumors. Tumor-specific brain TRM significantly improved survival and controlled tumor growth, even when circulating memory T cells were depleted. In contrast, TRM recognizing unrelated antigens did not provide protection, underscoring the importance of tumor specificity.

The study also demonstrated that brain TRM persisted long after tumor clearance, maintained their functionality, and protected against subsequent antigen-matched challenges. Mice harboring tumor-specific brain TRM experienced less tumor-associated immunosuppression and neuroinflammation than unvaccinated controls.

Importantly, peripheral administration of an mRNA-LNP vaccine generated functional, tumor-specific brain TRM without requiring direct immunization of the brain. These vaccine-induced cells retained cytotoxic activity and effectively controlled intracranial tumor growth.

Overall, the findings provide strong preclinical evidence that vaccination-induced brain TRM can serve as a durable immune surveillance system capable of preventing or limiting brain tumor establishment. The results support the development of personalized mRNA-based cancer vaccines as a promising strategy for cancer immunoprevention, particularly in individuals at risk for primary or metastatic brain tumors.

Rui He, graduate fellow, and Aliasger Salem, Bighley chair and professor, are contributing authors of the study entitled, "Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy."